New drug OBT076 targets cancer cells in early trial
NCT ID NCT04064359
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 20 times
Summary
This early-stage study tests a new drug called OBT076 in people with advanced solid tumors that have come back or spread. OBT076 is designed to find and attack cancer cells that have a specific protein (CD205) on their surface. The main goals are to find a safe dose and check for side effects, while also seeing if the drug can shrink tumors. About 200 adults whose cancer has not responded to standard treatments may join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Groeninge
COMPLETEDKortrijk, Belgium
-
Cedars-Sinai
COMPLETEDLos Angeles, California, 90048, United States
-
Centre Eugène Marquis
RECRUITINGRennes, France
Contact
-
Columbia University Medical Center
COMPLETEDNew York, New York, 10032, United States
-
EuroMedica
COMPLETEDThessaloniki, GR-54645, Greece
-
GHP Saint-Joseph
RECRUITINGParis, France
Contact
-
Hopital Saint Antoine
COMPLETEDParis, France
-
Hopital Saint Louis
RECRUITINGParis, France
Contact
-
Hospital Universitario Fundacion Jimenez Diaz
RECRUITINGMadrid, 28040, Spain
-
ICANS - Institut de cancérologie Strasbourg
RECRUITINGStrasbourg, France
Contact
-
Institut Gustave Roussy - IGR
RECRUITINGVillejuif, France
-
Institut Jules Bordet
RECRUITINGBrussels, Belgium
Contact
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
-
Mayo Clinic
COMPLETEDPhoenix, Arizona, 85084, United States
-
Metropolitan Hospital
COMPLETEDAthens, Greece
-
Moffitt Cancer Center
COMPLETEDTampa, Florida, 33612, United States
-
Quantum Santa Fe
COMPLETEDSanta Fe, New Mexico, 87505, United States
-
START Barcelona HM Nou Delfos
RECRUITINGBarcelona, 08023, Spain
-
Sotiria General Hospital
RECRUITINGAthens, Greece
Contact
-
St. Elizabeth Healthcare
COMPLETEDEdgewood, Kentucky, 41017, United States
-
The State University of Iowa
ACTIVE_NOT_RECRUITINGIowa City, Iowa, 52242, United States
-
UCLA
COMPLETEDSanta Monica, California, 90404, United States
-
University General Hospital Attikon
RECRUITINGChaïdári, Athens, 12462, Greece
Contact Phone: •••-•••-••••
Contact
Contact
-
University General Hospital of Heraklion
RECRUITINGHeraklion, Greece
Contact
-
University Hospital Marqués de Valdecilla
RECRUITINGSantander, 39008, Spain
-
University of Mississippi Medical Center
COMPLETEDJackson, Mississippi, 39216, United States
-
University of Pittsburgh
COMPLETEDPittsburgh, Pennsylvania, 15260, United States
Conditions
Explore the condition pages connected to this study.